Vancouver-based psychedelic extraction and drug discovery company Filament Health has secured CAD 1.0 million (USD 0.7 million) via bridge funding from Negev Capital Fund One and Benjamin Lightburn, Filament's CEO and co-founder. The funding round will close on June 10, 2024, pending regulatory approval.
The financing terms include Negev converting its warrants and a convertible note into common shares at a reduced price of CAD 0.05 (USD 0.04) per share, raising CAD 0.9 million (USD 0.7 million) for Filament. Additionally, Benjamin Lightburn will buy 2,700,000 shares at the same price, adding another CAD 0.1 million (USD 0.07 million).
The new funds will be allocated toward advancing its clinical development programs.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.